vs
Cricut, Inc.（CRCT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Cricut, Inc.的1.0倍（$207.3M vs $203.6M），Cricut, Inc.净利率更高（3.8% vs -62.0%，领先65.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -2.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 10.3%）
Cricut, Inc.是面向家庭手工爱好者的美国品牌，主营计算机控制的切割机产品。这类设备可切割纸张、毛毡、乙烯基、布料，也可加工皮革、纸板、木材等多种材料，是手工创作场景的实用工具。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CRCT vs RARE — 直观对比
营收规模更大
RARE
是对方的1.0倍
$203.6M
营收增速更快
RARE
高出28.6%
-2.7%
净利率更高
CRCT
高出65.8%
-62.0%
两年增速更快
RARE
近两年复合增速
10.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $203.6M | $207.3M |
| 净利润 | $7.8M | $-128.6M |
| 毛利率 | 47.4% | — |
| 营业利润率 | 6.8% | -54.7% |
| 净利率 | 3.8% | -62.0% |
| 营收同比 | -2.7% | 25.9% |
| 净利润同比 | -34.7% | 3.5% |
| 每股收益（稀释后） | $0.03 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRCTRARE
| Q4 25 | $203.6M | $207.3M | ||
| Q3 25 | $170.4M | $159.9M | ||
| Q2 25 | $172.1M | $166.5M | ||
| Q1 25 | $162.6M | $139.3M | ||
| Q4 24 | $209.3M | $164.6M | ||
| Q3 24 | $167.9M | $139.5M | ||
| Q2 24 | $167.9M | $147.0M | ||
| Q1 24 | $167.4M | $108.8M |
净利润CRCTRARE
| Q4 25 | $7.8M | $-128.6M | ||
| Q3 25 | $20.5M | $-180.4M | ||
| Q2 25 | $24.5M | $-115.0M | ||
| Q1 25 | $23.9M | $-151.1M | ||
| Q4 24 | $11.9M | $-133.2M | ||
| Q3 24 | $11.5M | $-133.5M | ||
| Q2 24 | $19.8M | $-131.6M | ||
| Q1 24 | $19.6M | $-170.7M |
毛利率CRCTRARE
| Q4 25 | 47.4% | — | ||
| Q3 25 | 55.2% | — | ||
| Q2 25 | 59.0% | — | ||
| Q1 25 | 60.5% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 46.1% | — | ||
| Q2 24 | 53.5% | — | ||
| Q1 24 | 54.7% | — |
营业利润率CRCTRARE
| Q4 25 | 6.8% | -54.7% | ||
| Q3 25 | 13.3% | -106.9% | ||
| Q2 25 | 17.5% | -64.8% | ||
| Q1 25 | 18.0% | -102.6% | ||
| Q4 24 | 6.6% | -74.3% | ||
| Q3 24 | 6.3% | -94.6% | ||
| Q2 24 | 15.7% | -79.1% | ||
| Q1 24 | 15.1% | -151.9% |
净利率CRCTRARE
| Q4 25 | 3.8% | -62.0% | ||
| Q3 25 | 12.0% | -112.8% | ||
| Q2 25 | 14.2% | -69.0% | ||
| Q1 25 | 14.7% | -108.5% | ||
| Q4 24 | 5.7% | -80.9% | ||
| Q3 24 | 6.8% | -95.7% | ||
| Q2 24 | 11.8% | -89.5% | ||
| Q1 24 | 11.7% | -156.8% |
每股收益（稀释后）CRCTRARE
| Q4 25 | $0.03 | $-1.28 | ||
| Q3 25 | $0.10 | $-1.81 | ||
| Q2 25 | $0.11 | $-1.17 | ||
| Q1 25 | $0.11 | $-1.57 | ||
| Q4 24 | $0.06 | $-1.34 | ||
| Q3 24 | $0.05 | $-1.40 | ||
| Q2 24 | $0.09 | $-1.52 | ||
| Q1 24 | $0.09 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $275.6M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $343.6M | $-80.0M |
| 总资产 | $580.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRCTRARE
| Q4 25 | $275.6M | $421.0M | ||
| Q3 25 | $207.1M | $202.5M | ||
| Q2 25 | $376.9M | $176.3M | ||
| Q1 25 | $356.7M | $127.1M | ||
| Q4 24 | $336.9M | $174.0M | ||
| Q3 24 | $246.9M | $150.6M | ||
| Q2 24 | $299.5M | $480.7M | ||
| Q1 24 | $281.7M | $112.3M |
股东权益CRCTRARE
| Q4 25 | $343.6M | $-80.0M | ||
| Q3 25 | $358.4M | $9.2M | ||
| Q2 25 | $308.9M | $151.3M | ||
| Q1 25 | $490.2M | $144.2M | ||
| Q4 24 | $466.8M | $255.0M | ||
| Q3 24 | $475.8M | $346.8M | ||
| Q2 24 | $448.5M | $432.4M | ||
| Q1 24 | $552.6M | $140.3M |
总资产CRCTRARE
| Q4 25 | $580.8M | $1.5B | ||
| Q3 25 | $564.3M | $1.2B | ||
| Q2 25 | $721.5M | $1.3B | ||
| Q1 25 | $681.7M | $1.3B | ||
| Q4 24 | $693.0M | $1.5B | ||
| Q3 24 | $663.8M | $1.5B | ||
| Q2 24 | $742.1M | $1.6B | ||
| Q1 24 | $723.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 10.58× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CRCTRARE
| Q4 25 | $82.4M | $-99.8M | ||
| Q3 25 | $20.5M | $-91.4M | ||
| Q2 25 | $36.2M | $-108.3M | ||
| Q1 25 | $61.2M | $-166.5M | ||
| Q4 24 | $103.1M | $-79.3M | ||
| Q3 24 | $70.2M | $-67.0M | ||
| Q2 24 | $35.0M | $-77.0M | ||
| Q1 24 | $56.7M | $-190.7M |
自由现金流CRCTRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率CRCTRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度CRCTRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率CRCTRARE
| Q4 25 | 10.58× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 2.56× | — | ||
| Q4 24 | 8.64× | — | ||
| Q3 24 | 6.11× | — | ||
| Q2 24 | 1.77× | — | ||
| Q1 24 | 2.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRCT
| Platform | $83.9M | 41% |
| Connected Machines | $65.2M | 32% |
| Accessories And Materials | $54.4M | 27% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
